Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma
Study Details
Study Description
Brief Summary
RATIONALE: Vaccines made from a patient's dendritic cells may make the body build an immune response to kill tumor cells. It is not yet known whether combining vaccine therapy with either gp100 antigen or the patient's tumor cells will cause a stronger immune response and kill more tumor cells.
PURPOSE: This randomized phase II trial is studying vaccine therapy and gp100 antigen to see how well they work compared to vaccine therapy and patient's tumor cells in treating patients with stage III or stage IV melanoma.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 2 |
Detailed Description
OBJECTIVES:
Primary
- Compare the tumor-specific immune response, in terms of the number of gp100-specific cytotoxic T-lymphocytes, T-cell production of interferon gamma, or T-cell proliferation in response to in vitro exposure to gp100 and tumor lysate, in patients with stage III or IV melanoma treated with autologous dendritic cells (DC) pulsed with gp100 antigen vs autologous DC fused with autologous tumor cells.
Secondary
-
Compare the safety and toxicity of these regimens in these patients.
-
Compare the therapeutic effect of these regimens in these patients.
OUTLINE: This is a randomized study. Patients are randomized to 1 of 2 treatment arms.
All patients undergo leukapheresis. Peripheral blood mononuclear cells are cultured to generate dendritic cells (DC).
-
Arm I: Patients undergo surgical harvesting of tumor cells for subsequent fusion. Patients receive vaccination comprising DC fused with autologous tumor cells subcutaneously on day 1. Treatment repeats every 21 days for 3 courses. Patients who achieve a partial (PR) or complete response (CR) may receive an additional 3 courses.
-
Arm II: Patients receive vaccination comprising DC pulsed with gp100 antigen IV on day
- Treatment repeats every 21 days for 6 courses. Patients who achieve a PR or CR may receive an additional 6 courses.
In both arms, patients are followed monthly for 6 months.
PROJECTED ACCRUAL: A total of 40 patients (20 per treatment arm) will be accrued for this study.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Arm I Patients undergo surgical harvesting of tumor cells for subsequent fusion. Patients receive vaccination comprising dendritic cells (DC) fused with autologous tumor cells subcutaneously on day 1. Treatment repeats every 21 days for 3 courses. Patients who achieve a partial (PR) or complete response (CR) may receive an additional 3 courses. |
Biological: autologous dendritic cell-tumor fusion vaccine
Given subcutaneously
|
| Experimental: Arm II Patients receive vaccination comprising DC pulsed with gp100 antigen IV on day 1. Treatment repeats every 21 days for 6 courses. Patients who achieve a PR or CR may receive an additional 6 courses. |
Biological: gp100 antigen
Given IV
Biological: therapeutic autologous dendritic cells
Given IV
|
Outcome Measures
Primary Outcome Measures
- Immune response []
Eligibility Criteria
Criteria
DISEASE CHARACTERISTICS:
-
Histologically confirmed cutaneous melanoma
-
Stage III or IV disease
-
Recurrent or de novo stage III disease allowed if disease is unresectable and no definitive treatment is available
-
gp100- and HLA-A201-positive
-
Surgically accessible tumor, defined by 1 of the following:
-
Pulmonary lesions approachable by thoracoscopic procedure
-
Skin or superficial soft tissue or lymph node lesions amenable to resection under local anesthesia
-
Malignant ascites or pleural effusion
-
Measurable disease in addition to surgically accessible tumor > 2.0 cm
-
No CNS metastases
-
No mucosal or ocular melanoma
PATIENT CHARACTERISTICS:
Age
- Any age
Performance status
- ECOG 0-1
Life expectancy
- More than 3 months
Hematopoietic
-
WBC > 3,000/mm^3
-
Platelet count > 75,000/mm^3
Hepatic
- Bilirubin < 2.0 mg/dL
Renal
- Creatinine < 2.0 mg/dL
Immunologic
-
No active infection requiring treatment
-
No clinically significant autoimmune disorder
-
No immune deficiency disorder
-
HIV negative
Other
-
Antecubital vein accessible for leukapheresis
-
No other malignancy within the past 5 years except nonmelanoma skin cancer or squamous cell carcinoma in situ of the cervix
-
No pre-existing comorbid disease that would preclude study compliance
-
Not pregnant or nursing
-
Negative pregnancy test
-
Fertile patients must use effective barrier contraception
PRIOR CONCURRENT THERAPY:
Biologic therapy
-
No prior melanoma vaccine therapy
-
More than 6 weeks since prior immunotherapy
Chemotherapy
- No prior chemotherapy for metastatic melanoma
Endocrine therapy
- No concurrent corticosteroids
Radiotherapy
- More than 6 weeks since prior radiotherapy
Surgery
- Not specified
Other
- No concurrent systemic immunosuppressive therapy
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Massachusetts General Hospital | Boston | Massachusetts | United States | 02114 |
| 2 | Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute | Boston | Massachusetts | United States | 02115 |
| 3 | Beth Israel Deaconess Medical Center | Boston | Massachusetts | United States | 02215 |
Sponsors and Collaborators
- Dana-Farber Cancer Institute
- National Cancer Institute (NCI)
Investigators
- Principal Investigator: Frank Haluska, MD, PhD, Massachusetts General Hospital
- Principal Investigator: David Avigan, MD, Beth Israel Deaconess Medical Center
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- CDR0000369699
- DFCI-03123